Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Antonio Jimenez Jimenez, MD, discusses the ACCESS trial of PTCy-based GVHD prophylaxis after mismatched unrelated donor stem ...

Joseph Jacob, MD, discusses the promising impact of TAR-200.

Anita Turk, MD, discusses abstracts from ASCO 2025 highlight the evolving role of ctDNA in the management of colorectal ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Panelists discuss how the evolution of anal cancer treatment began with the 1974 Nigro regimen combining 5-fluorouracil and ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Panelists discuss how successful treatment of locally advanced anal cancer requires a multidisciplinary approach involving ...

Anita Turk, MD, details her biggest takeaways from the 2025 ASCO Annual Meeting in gastrointestinal cancers. Anita Turk, MD, medical oncologist at IU Health, discusses her biggest takeaways in the ...

New research reveals that combining lurbinectedin with atezolizumab significantly improves survival rates for patients with ...

Panelists discuss that, based on EMERALD trial data, elacestrant provides consistent clinical benefit in metastatic breast ...

FDA accelerates approval of sunvozertinib for advanced NSCLC with EGFR mutations, offering new hope for patients after ...